Clinical Trials Using Eribulin Mesylate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Eribulin Mesylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-14 of 14
  • Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed / Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

    This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed / refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) to determine whether each cohort warrants further investigation.
    Location: 14 locations

  • Atezolizumab with or without Eribulin Mesylate in Treating Patients with Recurrent Locally Advanced or Metastatic Urothelial Cancer

    This phase II trial studies the side effects of atezolizumab with or without eribulin mesylate and how well they work in treating patients with urothelial cancer that has come back (recurrent), spread to nearby tissues and lymph nodes (locally advanced), or other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab and eribulin mesylate may work better at treating urothelial cancer compared to atezolizumab alone.
    Location: 7 locations

  • Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

    This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.
    Location: 8 locations

  • Selinexor with Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients with Advanced Malignancies

    This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Selinexor may stop the growth of cancer cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Studying selinexor with different standard chemotherapy or immunotherapy regimens may help doctors learn the side effects and best dose of selinexor that can be given with different types of treatments in one study.
    Location: 5 locations

  • Eribulin and Pembrolizumab in Treating Patients with Soft Tissue Sarcomas

    This phase II trial studies how well eribulin and pembrolizumab work in treating patients with soft tissue sarcomas such as liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma. Drugs used in chemotherapy, such as eribulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy treatment with eribulin may increase the response to immunotherapy with pembrolizumab in patients with soft tissue sarcomas.
    Location: 3 locations

  • A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer

    This is a Phase Ib / II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic or inoperable locally advanced TNBC. The study will be performed in two stages. During Stage 1, two cohorts will be enrolled in parallel in this study: one cohort will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line [1L] PD-L1+ cohort), and one cohort will consist of participants who had disease progression during or following 1L treatment with chemotherapy (e.g., paclitaxel, nab-paclitaxel, carboplatin) and have not received cancer immunotherapy (CIT) (second-line [2L] CIT-naive cohort). In addition, participants in the 2L CIT-naive cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment.
    Location: 3 locations

  • Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Angiosarcoma or Epithelioid Hemangioendothelioma

    This pilot phase II trial studies how well eribulin mesylate works in treating patients with angiosarcoma or epithelioid hemangioendothelioma that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 3 locations

  • Eribulin Mesylate Followed by Doxorubicin Hydrochloride and Cyclophosphamide in Treating Patients with HER2-Negative Inflammatory Breast Cancer before Surgery

    This phase II trial studies how well eribulin mesylate works in combination with doxorubicin hydrochloride and cyclophosphamide in treating patients with human epidermal growth factor receptor 2 (HER2)-negative inflammatory breast cancer before surgery. Eribulin mesylate works by interfering with cancer cell division, growth, and spread. Drugs used in chemotherapy, such as doxorubicin hydrochloride and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving eribulin mesylate together with doxorubicin hydrochloride and cyclophosphamide before surgery may be an effective treatment in HER2-negative inflammatory breast cancer patients.
    Location: 3 locations

  • M7824 and Eribulin Mesylate in Treating Patients with Metastatic Triple Negative Breast Cancer

    This phase Ib trial studies the best dose and side effects of eribulin mesylate when given together with M7824)in treating patients with triple negative breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as M7824, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving eribulin mesylate and M7824 may work better at treating triple negative breast cancer.
    Location: 2 locations

  • Evaluate Eribulin ORA in Subjects With Solid Tumors

    This is a nonrandomized, open-label, dosed escalation, safety activity, and PK study to determine the MTD and optimal dosing regimen of Eribulin ORA.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Eribulin Mesylate and Radiation Therapy in Treating Patients with Retroperitoneal Liposarcoma That Can Be Removed by Surgery

    This phase Ib trials studies the side effects and best dose of eribulin mesylate when given together with radiation therapy in treating patients with retroperitoneal liposarcoma that can be removed by surgery. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

    The Phase 1 part of the study is conducted to determine the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with relapsed / refractory solid tumors (excluding central nervous system [CNS] tumors). The Phase 2 part of the study is conducted to assess the objective response rate (ORR) and duration of response (DOR) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with relapsed / refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and ewing sarcoma (EWS).
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Rebastinib Tosylate and Paclitaxel or Eribuilin Mesylate in Treating Patients with HER2 Negative Metastatic Breast Cancer

    This phase Ib trial studies the best dose and side effects of rebastinib tosylate when given together with paclitaxel or eribulin mesylate in treating patients with HER2 negative breast cancer that has spread to other parts of the body. Rebastinib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rebastinib tosylate with paclitaxel or eribulin may work better in treating patients with breast cancer.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer

    This phase I / II trial studies the side effects and best dose of copanlisib and how well it works when given together with eribulin in treating patients with triple negative breast cancer that has spread to other places in the body (advanced stage). Copanlisib stops the growth of a protein called PI3K, which is often changed in tumor cells and causes resistance to treatment. Chemotherapy drugs, such as eribulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving copanlisib and eribulin may work better in treating advanced stage triple negative breast cancer compared to eribulin alone.
    Location: See Clinical Trials.gov